Precigen
Precigen is a biotechnology company that creates synthetic biology solutions by designing, building, and regulating gene programs for various end markets through exclusive collaborations with industry experts.
Precigen Overview
Precigen Funding Rounds
Round | Date | Amount Raised | Valuation | Investors | Sources |
---|---|---|---|---|---|
IPO | 8/8/2013 | ||||
Series F | 5/1/2013 | ||||
Later Stage | 4/25/2012 | ||||
Series E | 5/31/2011 | ||||
Later Stage | 5/6/2011 | ||||
Later Stage VC | 4/22/2011 |
Precigen Investors
Investor | Investment Rounds | Lead Partner | Initial Investment | Other Notable Investments |
---|---|---|---|---|
Third Point Ventures | Series F | Series F (2013-05-01) |
Precigen 409a Valuations
Date | Price per share | Est. Valuation | Filling |
---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Precigen Filings
Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Latest Precigen News
Precigen, Inc. (NASDAQ:PGEN) Given Consensus Rating of "Moderate Buy" by Brokerages
MarketBeatOctober 12, 2024
After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen
Fierce BiotechOctober 11, 2024
Precigen Terminates License Agreement With Alaunos Therapeutics
MarketWatchOctober 10, 2024
Precigen Regains Full Control of Technology Post Agreement Termination
TipRanksOctober 10, 2024
Precigen : Termination of Material Agreement Form 8 K
Marketscreener.comOctober 10, 2024
When Will Precigen, Inc. (NASDAQ:PGEN) Turn A Profit?
Simply Wall StOctober 8, 2024
Precigen (NASDAQ:PGEN) Shares Cross Below 200 Day Moving Average of $1.36
MarketBeatOctober 3, 2024
Precigen senior VP Jeffrey Perez quits By Investing.com
Investing.com CanadaSeptember 24, 2024